ReviewMaterials today. Bio2025
Natural killer cell membrane manipulation for augmented immune synapse and anticancer efficacy.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Article
- Multifunctional Hybrid Nanomedicines for Neurodegenerative Diseases: A Paradigm Shift from Rational Design to Clinical Translation.International journal of nanomedicine · 2026Review
- Amphiphilic Lipid-Single-Stranded DNA Conjugate-Mediated Cell Surface Engineering for Programmable Intercellular Tethering and Immune Synapse Formation.Biomaterials research · 2026Article
- CUL5-mediated ubiquitination in cancer cell therapy: context-dependent roles, molecular networks, and emerging therapeutic avenues.Frontiers in medicine · 2026Review
- Click Chemistry Mediated Immune Synapse Augmentation in Natural Killer Cell-Cancer Membrane Engagement and Facilitated Anticancer Efficacies of Natural Killer Cell Therapy.Biomaterials research · 2026Article
- A new era in CAR-NK cell therapy: from technological innovations to clinical applications.World journal of pediatrics : WJP · 2026Review
- Article
- Development of Natural Killer Cell-Drug Conjugates via Membrane-Installed Liposomes for Pancreatic Cancer Treatment.Biomaterials research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are proving a powerful platform in cancer immunotherapy due to their innate cytotoxicity and ability to recognize tumor cells independently of antigen presentation. In preclinical and clinical studies, engineered NK cells expressing chimeric antigen receptors (CARs) have demonstrated strong antitumor efficacy, showcasing the potential of genetic reprogramming to enhance specificity and activation. In parallel, biomaterial-assisted surface engineering has gained momentum as a complementary strategy, offering a genome-independent and modular means of customizing NK cell functionality. Recent advances in covalent conjugation, metabolic glycoengineering, bio-orthogonal click chemistry, and hydrophobic insertion using biomaterials have facilitated the precise presentation of targeting ligands and immunomodulatory molecules directly onto the NK cell membrane. These strategies support programmable cell-tumor interactions, while maintaining the native cytotoxicity of NK cells. Although several challenges remain, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.